Nanomedical Applications of Nanoparticles for Blood Coagulation Disorders

  • Agbaje LateefEmail author
  • Sunday Ayotunde Ojo
  • Joseph Adetunji Elegbede
  • Paul Oluwadamilare Akinola
  • Emmanuel Olufemi Akanni
Part of the Environmental Chemistry for a Sustainable World book series (ECSW, volume 14)


Nanotechnology has evolved as a novel multidisciplinary concept of the twenty-first century, abridging gaps in materials science, engineering, life sciences and medicine, with tremendous applications in diverse areas of human endeavours. Nanoparticles, which form critical components of nanoscience and nanotechnology, have also played prominent roles in extending the frontiers of applications of the emerging discipline. The metallic nanoparticles, owing to their unique optical, surface, chemical, biological, catalytic, electronic, and resonance properties have formed an epicentre of research in recent times, with major focus on synthesis and novel applications. A new line of application that has emerged is in the delivery of quality healthcare, leading to the offshoot of a sub-discipline, nanomedicine. A major health problem confronting man is the blood coagulation disorder, which often leads to cardiovascular diseases, with the attendant high mortality worldwide. The use of conventional drugs in the treatment blood coagulation has been plagued with problems of high cost, short-lived action and adverse severe reactions. Hence, there is need to search for newer treatment regimes with improved outcomes, of which nanotechnology holds a promising future. In this review, we focus on the emerging applications of metallic nanoparticles in the management of blood coagulation disorders; notably in the prevention of clot formation, dissolution of blood clots, and in the combined role of therapeutic and diagnostic agents. The review presents a comprehensive overview on blood coagulation disorders, synthesis and applications of metallic nanoparticles, and the novel management of blood coagulation disorders using nanoplatform deliveries. Emphasis has been placed on the prospects of the use of metallic nanoparticles such as silver, gold and silver-gold alloy nanoparticles as anticoagulant, thrombolytic and theranostic agents, with evidences of excellent performances in the prevention of blood clot formation, dissolution of blood clots, and enhanced imaging of thrombus (blood clot) in vivo. The increasing appraisals of these nanoplatforms, potent action, improved biocompatibility cum absence of complications of excessive bleeding are good indicators of potential future integration in the clinical management of blood coagulation disorders. However, diligent studies are needed to be conducted to establish the long-term safety of applications of these nanomedical materials. The compendium seeks to bring to the fore, the continued relevance of nanotechnology in the twenty-first century, and its potential dynamic integration into medicare programmes.


Blood coagulation disorders Anticoagulation Thrombolysis Nanotechnology Nanoparticles Nanomedicine Cardiovascular diseases Theranostics Green synthesis Healthcare 



AL is grateful to the authority of LAUTECH., Ogbomoso, Nigeria for the support to his laboratory on some of the works on nanoscience and nanotechnology that are cited in this article.


  1. Abid JP, Wark AW, Brevet PF, Girault HH (2002) Preparation of silver nanoparticles in solution from silver salt by laser irradiation. Chem Commun 7:792–793. CrossRefGoogle Scholar
  2. Adelere IA, Lateef A (2016) A novel approach to the green synthesis of metallic nanoparticles: the use of agro-wastes, enzymes, and pigments. Nanotechnol Rev 5:567–587. CrossRefGoogle Scholar
  3. Aggeler PM, White SG, Glendenning MB, Page EW, Leake TB, Bates G (1952) Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc Soc Exp Biol Med 79:692–694CrossRefGoogle Scholar
  4. Ahmad T, Wani IA, Manzoor N, Ahmed J, Asiri AM (2013) Biosynthesis, structural characterization and antimicrobial activity of gold and silver nanoparticles. Colloids Surf B Biointerfaces 107:227–234. CrossRefGoogle Scholar
  5. Ahmed N, Fessi H, Elaissari A (2012) Theranostic applications of nanoparticles in cancer. Drug Discov Today 17:928–934. CrossRefGoogle Scholar
  6. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S (2010) Alzheimer’s disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A 107:21812–21817. CrossRefGoogle Scholar
  7. Alexander V, Goldstein R, Landwehr G, Cook C (1951) Coagulation serum prothrombin conversion accelerator (SPCA) deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fraction. J Clin Investig 30:596–608CrossRefGoogle Scholar
  8. Alzahrani SH, Ajjan RA (2010) Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res 7:260–273. CrossRefGoogle Scholar
  9. Asharani PV, Hande MP, Valiyaveettil S (2009) Anti-proliferative activity of silver nanoparticles. BMC Cell Biol 10:65–72. CrossRefGoogle Scholar
  10. Azeez MA, Lateef A, Asafa TB, Yekeen TA, Akinboro A, Oladipo IC, Gueguim-Kana EB, Beukes LS (2017a) Biomedical applications of cocoa bean extract-mediated silver nanoparticles as antimicrobial, larvicidal and anticoagulant agents. J Clust Sci 28:149–164. CrossRefGoogle Scholar
  11. Azeez L, Lateef A, Adebisi SA (2017b) Silver nanoparticles (AgNPs) biosynthesized using pod extract of Cola nitida enhances antioxidant activity and phytochemical composition of Amaranthus caudatus Linn. Appl Nanosci. 7: 59-66. CrossRefGoogle Scholar
  12. Bae KH, Chung HJ, Park TG (2011) Nanomaterials for cancer therapy and imaging. Mol Cell 31:295–302. CrossRefGoogle Scholar
  13. Banach M, Szczyglowska R, Pulit J, Bryk M (2014) Building materials with antifungal efficacy enriched with silver. Chem Sci J 5:1–5. CrossRefGoogle Scholar
  14. Bateman RM, Ellis CG, Suematsu M, Walley KR (2012) S-Nitrosoglutathione acts as a small molecule modulator of human fibrin clot architecture. PLoS One 7:e43660. CrossRefGoogle Scholar
  15. Benelli G (2016) Plant-mediated biosynthesis of nanoparticles as an emerging tool against mosquitoes of medical and veterinary importance: a review. Parasitol Res 115:23–34. CrossRefGoogle Scholar
  16. Bhattacharjee P, Bhattacharyya D (2014) An insight into the abnormal fibrin clots-Its pathophysiological roles. In: Kolev K (ed) Fibrinolysis and thrombolysis. Intech Publishers, Croatia, pp 3–29. ISBN:978-953-51-1265-5Google Scholar
  17. Bhattacharya R, Mukherjee P (2008) Biological properties of “naked” metal nanoparticles. Adv Drug Deliv Rev 60:1289–1306. CrossRefGoogle Scholar
  18. Bi F, Zhang J, Su Y, Tang YC, Liu JN (2009) Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials 30:5125–5130. CrossRefGoogle Scholar
  19. Blaser SA, Scheringer M, MacLeod M, Hungerbuhler K (2008) Estimation of cumulative aquatic exposure and risk due to silver: contribution of nano­functionalized plastics and textiles. Sci Total Environ 390:396–409. CrossRefGoogle Scholar
  20. Braun M, Burda C, El-Sayed MA (2001) Variation of the thickness and number of wells in the CdS/HgS/CdS quantum dot quantum well system. J Phys Chem A 105:5548–5551. CrossRefGoogle Scholar
  21. Braun RM, Cheng J, Parsonage EE, Moeller J, Winograd N (2006) Surface and depth profiling investigation of a drug-loaded copolymer utilized to coat Taxus Express(2) stents. Ann Chem 78:8347–8353. CrossRefGoogle Scholar
  22. Briggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'brien JR (1952) Christmas disease: a condition previously mistaken for haemophilia. Brit Med 2:1378–1382CrossRefGoogle Scholar
  23. Brito L, Amiji M (2007) Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine 2:143–161CrossRefGoogle Scholar
  24. Buxton DB (2009) Nanomedicine for the management of lung and blood diseases. Nanomedicine 4:331–339. CrossRefGoogle Scholar
  25. Carpenter SL, Mathew P (2008) Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 14:1250–1254. CrossRefGoogle Scholar
  26. Carr ME, Carr SL, Martin EJ, Johnson BA (2001) Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine – a case report. Angiology 52:361–366. CrossRefGoogle Scholar
  27. Castellano JJ, Shafii SM, Ko F, Donate G, Wright TE, Mannari RJ, Payne WG, Smith DJ, Robson MC (2007) Comparative evaluation of silver-containing antimicrobial dressings and drugs. Int Wound J 4:114–122. CrossRefGoogle Scholar
  28. Cengelli F, Maysinger D, Tschudi-Monnet F, Montet X, Corot C, Petri-Fink A, Hofmann H, Juillerat-Jeanneret L (2006) Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structure. J Pharmacol Exp Therapeut 318:108–116. CrossRefGoogle Scholar
  29. Chambers E, Mitragotri S (2004) Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release 100:111–119. CrossRefGoogle Scholar
  30. Cicha I (2015) Thrombosis: novel nanomedical concepts of diagnosis and treatment. World J Cardiol 7:434–441. CrossRefGoogle Scholar
  31. Clemetson KJ, Clemetson JM (2001) Platelet collagen receptors. Thromb Haemost 86:189–197CrossRefGoogle Scholar
  32. Cole AJ, Yang VC, David AE (2011) Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol 29:323–332. CrossRefGoogle Scholar
  33. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM (2005) Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med 53:999–1005. CrossRefGoogle Scholar
  34. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM (2008) Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol 28:820–826. CrossRefGoogle Scholar
  35. Davalos D, Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34:43–62. CrossRefGoogle Scholar
  36. De Gopegui RR, Feldman BF (1997) von Willebrand’s disease. Compar Haematol Int 7:187–196. CrossRefGoogle Scholar
  37. Devi CS, Mohanasrinivasan V, Tarafder A, Shishodiya E, Vaishnavi B, Jemimah NS (2016) Combination of clot buster enzymes and herbal extracts: a new alternative for thrombolytic drugs. Biocatal Agric Biotechnol 8:152–157. CrossRefGoogle Scholar
  38. Diamond SL, Anand S (1993) Inner clot diffusion and permeation during fibrinolysis. Biophys J 65:2622–2643. CrossRefGoogle Scholar
  39. Dirienzo M (2006) New applications for silver. The LBMA precious metals conference 2006, Montreux, pp 85–89Google Scholar
  40. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–360. CrossRefGoogle Scholar
  41. Ehmann HM, Breitwieser D, Winter S, Gspan C, Koraimann G, Maver U, Sega M, Köstler S, Stana-Kleinschek K, Spirk S, Ribitsch V (2015) Gold nanoparticles in the engineering of antibacterial and anticoagulant surfaces. Carbohydr Polym 117:34–42. CrossRefGoogle Scholar
  42. Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb Haemost 9:182–188. CrossRefGoogle Scholar
  43. Espinosa-Cristóbal LF, Martínez-Castañón GA, Martínez-Martínez RE, Loyola-Rodriguez JP, Patino-Marin N, Reyes-Macias JF, Ruiz F (2009) Antimicrobial effects of nanoparticles against Streptococcus mutans. Mater Lett 63:2603–2606. CrossRefGoogle Scholar
  44. Fan J, Kapus A, Li YH, Rizoli S, Marshall JC, Rotstein OD (2000) Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role tumor necrosis factor. Am J Respir Cell Mol Biol 22:412–421. CrossRefGoogle Scholar
  45. Farahani RM, DiPietro LA (2008) Microgravity and the implications for wound healing. Int Wound J 5:552–561. CrossRefGoogle Scholar
  46. Fedan JS (2003) Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) drugs. In: Craig CR, Stitzel RE (eds) Modern pharmacology with clinical applications, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 269–278Google Scholar
  47. Gade AK, Ingle A, Bawaskar M, Rai M (2009) Fusarium solani: a novel biological agent for the extracellular synthesis of silver nanoparticles. J Nanopart Res 11:2079–2085. CrossRefGoogle Scholar
  48. Gamez G, Gardea-Torresdey JL, Tiemann KJ, Parsons J, Dokken K, Yacaman J (2003) Recovery of gold (III) from multi-elemental solutions by alfalfa biomass. Adv Environ Res 7:563–571. CrossRefGoogle Scholar
  49. Gaylarde CC, Morton LHG, Loh K, Shirakawa MA (2011) Biodeterioration of external architectural paint films- a review. Int Bioteriorior 65:1189–1198. CrossRefGoogle Scholar
  50. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M (2010) Emerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseases. Trends Pharmacol Sci 31:199–205. CrossRefGoogle Scholar
  51. Gutstein DE, Fuster V (1999) Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 41:323–333. CrossRefGoogle Scholar
  52. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM (2011) Nanoparticles as contrast agents for in vivo bioimaging: current status and future perspectives. Anal Bioanal Chem 399:3–27. CrossRefGoogle Scholar
  53. Harish BS, Uppuluri KB, Anbazhagan V (2015) Synthesis of fibrinolytic active nanoparticles using wheat bran xylan as a reducing and stabilizing agent. Carbohydr Polym 132:104–110. CrossRefGoogle Scholar
  54. Herman WW, Konzelman JL, Sutley SH (1997) Current perspectives on dental patients receiving coumarin anticoagulant therapy. J Amer Dental Assoc 128:327–335. CrossRefGoogle Scholar
  55. Hildebrandt N, Hermsdorf D, Signorell R, Schmitz SA, Diederichsen U (2007) Superparamagnetic iron oxide nanoparticles functionalized with peptides by electrostatic interaction. ARKIVOC 5:79–90Google Scholar
  56. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT (1998a) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114:445S–469SCrossRefGoogle Scholar
  57. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998b) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114:489S–510SCrossRefGoogle Scholar
  58. Huang H, Yang X (2004) Synthesis of polysaccharide-stabilized gold and silver nanoparticles: a green method. Carbohydr Res 339:2627–2631. CrossRefGoogle Scholar
  59. Huang YF, Lin YW, Lin ZH, Chang HTJ (2009) Aptermer-modified gold nanoparticles for targeting breast cancer cells through light scattering. J Nanopart Res 11:775–783. CrossRefGoogle Scholar
  60. Idell S, Peters J, James KK, Fair DS, Coalson JJ (1989) Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Investig 84:181–193. CrossRefGoogle Scholar
  61. Ilinskaya AN, Dobrovolskaia MA (2013) Nanoparticles and the blood coagulation system. Part I: Benefits of nanotechnology. Nanomedicine 8:773–784. CrossRefGoogle Scholar
  62. Ingelsten HH, Bagwe R, Palmqvist A, Skoglundh M, Svanberg C, Holmberg K, Shah D (2001) Kinetics of the formation of nanosized platinum particles in water-in-oil microemulsions. J Colloid Interf Sci 241:104–111. CrossRefGoogle Scholar
  63. Ingle A, Gade A, Pierrat S, Sonnichsen C, Rai MK (2008) Mycosynthesis of silver nanoparticles using fungus Fusarium acuminatum and its activity against some human pathogenic bacteria. Curr Nanosci 4:141–144. CrossRefGoogle Scholar
  64. Jaberi A, Lum C, Stefanski P, Thornhill R, Iancu D, Petrcich W, Momoli F, Torres C, Dowlatshahi D (2014) Computed tomography angiography intraluminal filling defect is predictive of internal carotid artery free-floating thrombus. Neuroradiology 56:15–23. CrossRefGoogle Scholar
  65. Janib SM, Moses AS, MacKay JA (2010) Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62:1052–1063. CrossRefGoogle Scholar
  66. Jeelani S, Reddy RJ, Maheswaran T, Asokan GS, Dany A, Anand B (2014) Theranostics: a treasured tailor for tomorrow. J Pharm BioAllied Sci 6:6–8. CrossRefGoogle Scholar
  67. Johnson J, Kushowski M, Wilt T (2006) Systematic review: antimicrobial urinary catheters prevent Catheter-associated urinary tract infections in hospitalized patients. Ann Intern Med 144:116–122. CrossRefGoogle Scholar
  68. Johri P, Nagare S, Swamy KW, Kumar CS (2011) An insight into blood clotting disorders in humans. J Comput Biol Bioinf Res 3:8–14. Article Number – 6A0AB848835Google Scholar
  69. Kaida T, Kobayashi K, Adachi M, Suzuki F (2004) Optical characteristics of titanium oxideinterference film and the film laminated with oxides and their applications for cosmetics. J Cosmet Sci 55:219–220Google Scholar
  70. Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjug Chem 22:1879–1903. CrossRefGoogle Scholar
  71. Khan MS, Vishakante GD, Siddaramaiah H (2013) Gold nanoparticles: a paradigm shift in biomedical applications. Adv Colloid Interf Sci 199:44–58. CrossRefGoogle Scholar
  72. Kievit FM, Zhang M (2011) Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater 23:217–247. CrossRefGoogle Scholar
  73. Kim E, Kim OV, Machlus KR, Liu X, Kupaev T, Lioi J, Wolberg AS, Chen DZ, Rosen ED, Xua Z, Alber M (2011) Correlation between fibrin network structure and mechanical properties: an experimental and computational analysis. Soft Matter 7:4983–4992. CrossRefGoogle Scholar
  74. Kim HK, Choi MJ, Cha SH, Koo YK, Jun SH, Cho S, Park Y (2013a) Earthworm extracts utilized in the green synthesis of gold nanoparticles capable of reinforcing the anticoagulant activities of heparin. Nanoscale Res Lett 8:542. CrossRefGoogle Scholar
  75. Kim DE, Kim JY, Sun IC, Schellingerhout D, Lee SK, Ahn CH, Kwon IC, Kim K (2013b) Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles. Ann Neurol 73:617–625. CrossRefGoogle Scholar
  76. Kim JY, Ryu JH, Schellingerhout D, Sun IC, Lee SK, Jeon S, Kim J, Kwon IC, Nahrendorf M, Ahn CH, Kim K (2015) Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles. Theranostics 5:1098–1114. CrossRefGoogle Scholar
  77. Kirmani JF, Alkawi A, Panezai S, Gizzi M. (2012). Advances in thrombolytics for treatment of acute ischemic stroke. Neurology 79:119–125. 10.​1212/​WNL.​0b013e3182695882CrossRefGoogle Scholar
  78. Kotb E (2012) Fibrinolytic bacterial enzymes with thrombolytic activity. SpringerBriefs in Microbiology. pp 1–74.
  79. Kowshik M, Ashataputre S, Kharrazi S, Kulkami SK, Paknikari KM, Vogel W, Urban J (2002) Extracellular synthesis of silver nanoparticles by a silver-tolerant yeast strain MKY3. Nanotechnology 14:95–100. CrossRefGoogle Scholar
  80. Krug JT, Wang GD, Emory SR, Nie S (1999) Efficient Raman enhancement and intermittent light emission observed in single gold nanocrystals. J Am Chem Soc 121:9208–9214. CrossRefGoogle Scholar
  81. Kujovich JL (2005) Hemostatic defects in end stage liver disease. Crit Care Clin 21(3):563–587. CrossRefGoogle Scholar
  82. Kumar A, Vemula PK, Ajayan PM, John G (2008) Silver-nanoparticles-embedded antimicrobial paints based on vegetable oil. Nat Mater 7:236–241. CrossRefGoogle Scholar
  83. Kvistek L, Prucek R (2005) The preparation and application of silver nanoparticles. J Mater Sci 22:2451–2473Google Scholar
  84. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen LK, Fuhrhop RW, Scherrer DE, Wickline SA (2002) Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106:2842–2847. CrossRefGoogle Scholar
  85. Lateef A, Adeeyo AO (2015) Green synthesis and antibacterial activities of silver nanoparticles using extracellular laccase of Lentinus edodes. Notulae Scientia Biologicae 7:405–411. CrossRefGoogle Scholar
  86. Lateef A, Adelere IA, Gueguim-Kana EB, Asafa TB, Beukes LS (2015a) Green synthesis of silver nanoparticles using keratinase obtained from a strain of Bacillus safensis LAU 13. Int Nano Lett 5:29–35. CrossRefGoogle Scholar
  87. Lateef A, Azeez MA, Asafa TB, Yekeen TA, Akinboro A, Oladipo IC, Ajetomobi FE, Gueguim-Kana EB, Beukes LS (2015b) Cola nitida mediated biogenic synthesis of silver nanoparticles using seed and seed shell extracts and evaluation of antibacterial activities. Bio Nano Sci 5:196–205. CrossRefGoogle Scholar
  88. Lateef A, Ojo SA, Akinwale AS, Azeez L, Gueguim-Kana EB, Beukes LS (2015c) Biogenic synthesis of silver nanoparticles using cell-free extract of Bacillus safensis LAU 13: antimicrobial, free radical scavenging and larvicidal activities. Biologia 70:1295–1306. CrossRefGoogle Scholar
  89. Lateef A, Ojo SA, Oladejo SM (2016a) Anti-candida, anti-coagulant and thrombolytic activities of biosynthesized silver nanoparticles using cell-free extract of Bacillus safensis LAU 13. Process Biochem 51:1406–1412. CrossRefGoogle Scholar
  90. Lateef A, Azeez MA, Asafa TB, Yekeen TA, Akinboro A, Oladipo IC, Azeez L, Ajibade SE, Ojo SA, Gueguim-Kana EB, Beukes LS (2016b) Biogenic synthesis of silver nanoparticles using a pod extract of Cola nitida: antibacterial, antioxidant activities and application as a paint additive. J Taibah Univ Sci 10:551–562. CrossRefGoogle Scholar
  91. Lateef A, Azeez MA, Asafa TB, Yekeen TA, Akinboro A, Oladipo IC, Azeez L, Ojo SA, Gueguim-Kana EB, Beukes LS (2016c) Cocoa pod extract-mediated biosynthesis of silver nanoparticles: its antimicrobial, antioxidant and larvicidal activities. J Nanostruct Chem 6:159–169. CrossRefGoogle Scholar
  92. Lateef A, Akande MA, Azeez MA, Ojo SA, Folarin BI, Gueguim-Kana EB, Beukes LS (2016d) Phytosynthesis of silver nanoparticles (AgNPs) using miracle fruit plant (Synsepalum dulcificum) for antimicrobial, catalytic, anticoagulant, and thrombolytic applications. Nanotechnol Rev 5:507–520. CrossRefGoogle Scholar
  93. Lateef A, Ojo SA, Folarin BI, Gueguim-Kana EB, Beukes LS (2016e) Kola nut (Cola nitida) mediated synthesis of silver-gold alloy nanoparticles: antifungal, catalytic, larvicidal and thrombolytic applications. J Clust Sci 27:1561–1577. CrossRefGoogle Scholar
  94. Lateef A, Ojo SA, Azeez MA, Asafa TB, Yekeen TB, Akinboro A, Oladipo IC, Gueguim-Kana EB, Beukes LS (2016f) Cobweb as novel biomaterial for the green and eco-friendly synthesis of silver nanoparticles. Appl Nanosci. 6: 863-874. CrossRefGoogle Scholar
  95. Lateef A, Akande MA, Ojo SA, Folarin BI, Gueguim-Kana EB, Beukes LS (2016g) Paper wasp nest-mediated biosynthesis of silver nanoparticles for antimicrobial, catalytic, anticoagulant, and thrombolytic applications. 3 Biotech 6:140. CrossRefGoogle Scholar
  96. Lateef A, Ojo SA, Elegbede JA (2016h) The emerging roles of arthropods and their metabolites in the green synthesis of metallic nanoparticles. Nanotechnol Rev 5:601–622. CrossRefGoogle Scholar
  97. Lateef A, Ojo SA, Elegbede JA, Azeez MA, Yekeen TA, Akinboro A (2017) Evaluation of some biosynthesized silver nanoparticles for biomedical applications: hydrogen peroxide scavenging, anticoagulant and thrombolytic activities. J Clust Sci 28:1379–1392. CrossRefGoogle Scholar
  98. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations and biological applications. Chem Rev 108:2064–2110. CrossRefGoogle Scholar
  99. Lefkowitz JB (2008) Coagulation pathway and physiology. An algorithmic approach to hemostasis testing. College of American Pathologists, NorthfieldGoogle Scholar
  100. Lengke FM, Fleet EM, Southam G (2007) Biosynthesis of silver nanoparticle by filamentous cyanobacteria a from a silver (I) nitrate complex. Langmuir 23:2694–2699. CrossRefGoogle Scholar
  101. Li J, Gupta S, Li C (2013) Research perspectives: gold nanoparticles in cancer theranostics. Quant Imaging Med Surg 3:284–291. CrossRefGoogle Scholar
  102. Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225–1228. CrossRefGoogle Scholar
  103. Libby P (2012) Inflammation in atherosclerosis. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045–2051. CrossRefGoogle Scholar
  104. Linkov I, Satterstrom FK, Corey LM (2008) Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine 4:167–171. CrossRefGoogle Scholar
  105. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121:131–139. CrossRefGoogle Scholar
  106. Luoma SN (2008) Silver nanotechnologies and the environment: old problems or new challenges? Project on Emerging Nanotechnologies. The Pew Charitable Trusts. Accessed on 20 Feb 2017
  107. Lyer S, Tietze R, Jurgons R, Richter H, Wiekhorst F, Schwarz K, Trahms L, Alexiou C (2006) Distribution of magnetic nanoparticles after magnetic drug targeting in an ex vivo Bovine Artery Model. World Congress on Medical Physics and Biomedical Engineering, September 7-12, 2009, Munich, Germany. IFMBE Proc 25:484–487. CrossRefGoogle Scholar
  108. Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914–918. CrossRefGoogle Scholar
  109. Majerus PW (2001) Platelets. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H (eds) The molecular basis of blood disease, 3rd edn. WB Saunders Company, Philadelphia, pp 764–790Google Scholar
  110. Mammen EF (1994) Coagulation defects in liver disease. Med Clin North Am 78:545–554. CrossRefGoogle Scholar
  111. Marazzi M, De Angelis A, Ravizza A, Ordanini MN, Falcone L, Chiaratti A, Crovato F, Calò D, Veronese S, Rapisarda V (2007) Successful management of deep facial burns in patient with extensive third degree burns: the role of a nanocrystalline dressing in facilitating resurfacing. Int Wound J 4:8–14. CrossRefGoogle Scholar
  112. McCarthy JR, Jaffer FA (2011) The role of nanomedicine in the imaging and therapy of thrombosis. Nanomedicine 6:1291–1293. CrossRefGoogle Scholar
  113. McCarthy JR, Korngold E, Weissleder R, Jaffer FA (2010) A light activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6:2041–2049. CrossRefGoogle Scholar
  114. McCarthy JR, Sazonova IY, Erdem SS, Hara T, Thompson BD, Patel P, Botnaru I, Lin CP, Reed GL, Weissleder R, Jaffer FA (2012) Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy. Nanomedicine 7:1017–1028. CrossRefGoogle Scholar
  115. Miller VM, Hunter LW, Chu K, Kaul V, Squillace PD, Lieske JC, Jayachandran M (2009) Biologic nanoparticles and platelet reactivity. Nanomedicine 4:725–733. CrossRefGoogle Scholar
  116. Mohanpuria P, Rana NK, Yadav SK (2008) Biosynthesis of nanoparticles: technological concepts and future applications. J Nanopart Res 10:507–517. CrossRefGoogle Scholar
  117. Mokhtari M, Deneshpojouh S, Seyedbagheri S, Atashdehghan R, Abdi K, Sarkar S, Sharverdi RA (2009) Biological synthesis of very small silver nanoparticles by culture supernatant of Klebsiella pneumoniae: the effect of visible-light irradiation and the liquid mixing process. Mater Res Bull 44:1415–1421. CrossRefGoogle Scholar
  118. Monroe DM, Hoffman M, Roberts HR (2002) Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381139. CrossRefGoogle Scholar
  119. Morawitz P (1958) The chemistry of blood coagulation. Die Chemie der Blutgerinnung (trans: Hartmann R, Guenter PF). Charles C Thomas, SpringfieldGoogle Scholar
  120. Moulton KS (2006) Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol 17:548–555. CrossRefGoogle Scholar
  121. Mude N, Ingle A, Gade A, Rai M (2009) Synthesis of silver nanoparticles using callus extract of Carica papaya – a first report. J Biochem Biotechnol 18:83–86. CrossRefGoogle Scholar
  122. Mukherjee S, Chowdhury D, Kotcherlakota R, Patra S, Kumar V, Bhadra MP, Sreedhar B, Patra CR (2014) Potential theranostics application of bio-synthesized silver nanoparticles (4-in-1 system). Theranostics 4:316–335. CrossRefGoogle Scholar
  123. Nam J, Won N, Jin H, Chung H, Kim S (2009) pH-induced aggregation of gold nanoparticles for photothermal cancer therapy. J Am Chem Soc 131:13639–13645. CrossRefGoogle Scholar
  124. Nathan DG, Orkin SH, Ginsburg D, Look TA (2003) Nathan and Oski’s hematology of infancy and childhood (6th edn). Saunders, PhiladelphiaGoogle Scholar
  125. Ni J, Lipert RJ, Dawson GB, Porter MD (1999) Immunoassay readout method using extrinsic Raman labels adsorbed on immunogold colloids. Anal Chem 71:4903–4908. CrossRefGoogle Scholar
  126. Nichols WL, Bowie EJ (2001) A history of blood coagulation: Charles A. Owen, Jr. Mayo Foundation for Medical Education and Research, RochesterGoogle Scholar
  127. Nunes CR, Roedersheimer MT, Simske SJ, Luttges MW (1995) Effect of microgravity, temperature, and concentration on fibrin and collagen assembly. Microgravity Sci Technol 8:125–130Google Scholar
  128. Ojo SA, Lateef A, Azeez MA, Oladejo SM, Akinwale AS, Asafa TB, Yekeen TA, Akinboro A, Oladipo IC, Gueguim-Kana EB, Beukes LS (2016) Biomedical and catalytic applications of gold and silver-gold alloy nanoparticles biosynthesized using cell-free extract of Bacillus Safensis LAU 13: antifungal, dye degradation, anti-coagulant and thrombolytic activities. IEEE Trans Nanobiosci 15:433–442. CrossRefGoogle Scholar
  129. Oladipo IC, Lateef A, Elegbede JA, Azeez MA, Asafa TB, Yekeen TA, Akinboro A, Gueguim-Kana EB, Beukes LS, Oluyide TO, Atanda OR (2017a) Enterococcus species for the one-pot biofabrication of gold nanoparticles: characterization and nanobiotechnological applications. J Photochem Photobiol B Biol 173:250–257. CrossRefGoogle Scholar
  130. Oladipo IC, Lateef A, Azeez MA, Asafa TB, Yekeen TA, Akinboro A, Akinwale AS, Gueguim-Kana EB, Beukes LS (2017b) Green synthesis and antimicrobial activities of silver nanoparticles using cell-free extracts of Enterococcus species. Notulae Scientia Biologicae 9:196–203. CrossRefGoogle Scholar
  131. Olajire AA, Abidemi JJ, Lateef A, Benson NU (2017) Adsorptive desulphurization of model oil by Ag nanoparticles-modified activated carbon prepared from brewer’s spent grains. J Environ Chem Eng 5:147–159. CrossRefGoogle Scholar
  132. Owren PA (1947) The coagulation of blood: Investigations on a new clotting factor. Acta Med Scand 194:521–549Google Scholar
  133. Pan D, Senpan A, Caruthers SD, Williams TA, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM (2009) Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun 22:3234–3236. CrossRefGoogle Scholar
  134. Patek J, Stetson RH (1936) Hemophilia: I. The abnormal coagulation of blood and its relation to the blood platelets. J Clin Invest 15:531–542. CrossRefGoogle Scholar
  135. Patton LL (2003) Bleeding and clotting disorders. Burket’s Oral Medicine: diagnosis and treatment, 10th edn. BC Decker, Hamilton, pp 454–477Google Scholar
  136. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760. CrossRefGoogle Scholar
  137. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E (2009) Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci 106:9815–9819. CrossRefGoogle Scholar
  138. Prandoni P, Falanga A, Piccioli A (2007) Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 120:S137–S140. CrossRefGoogle Scholar
  139. Qu L, Peng ZA, Peng X (2001) Alternative routes toward high quality CdSe nanocrystals. Nano Lett 1:333–337. CrossRefGoogle Scholar
  140. Ragaseema VM, Unnikrishnan S, Krishnan VK, Krishnan LK (2012) The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. Biomaterials 33:3083–3092. CrossRefGoogle Scholar
  141. Rai M, Yadav A, Gade A (2008) Current trends in phytosynthesis of metal nanoparticles. Crit Rev Biotechnol 28:277–284CrossRefGoogle Scholar
  142. Rai MK, Yadav AP, Gade AK (2009) Silver as new generation of antimicrobials. Biotechnol Adv 27:76–83. CrossRefGoogle Scholar
  143. Rajarathinam M, Dhanpal D, Morukattu G, Joseph S, Thangavelu KP (2014) Imparting potential antimicrobial and antifungal activities to water based interior paint using nanoparticles of silver as an additive-An eco-friendly approach. Adv Sci Eng Med 6:676–682. CrossRefGoogle Scholar
  144. Raut R, Jaya SL, Niranjan DK, Vijay B, Kashid S (2009) Phytosynthesis of silver nanoparticle using Gliricidia sepium (Jacq.) Curr Nanosci 5:117–122CrossRefGoogle Scholar
  145. Riddel JP Jr, Aouizerat BE, Miaskowski C, Lillicrap DP (2007) Theories of Blood Coagulation. J Pediatr Oncol Nurs 3:123–131CrossRefGoogle Scholar
  146. Roberts HR, Stinchcombe TE, Gabriel DA (2001) The dysfibrinogenaemias. Br J Haematol 114:249–257. CrossRefGoogle Scholar
  147. Roopan SM, Madhumitha G, Rahuman AA, Kamaraj C, Bharathi A, Surendra TV (2013) Low-cost and eco-friendly phyto-synthesis of silver nanoparticles using Cocos nucifera coir extract and its larvicidal activity. Ind Crops Prod 43:631–635. CrossRefGoogle Scholar
  148. Rosenthal RL, Dreskinoff OH, Rosenthal N (1953) New hemophilia-like disease caused by a deficiency of a third plasma thromboplastin factor. Exp Biol Med 82:171–174. CrossRefGoogle Scholar
  149. Rottenberger Z, Komorowicz E, Szabó L, Bóta A, Varga Z, Machovich R, Longstaff C, Kolev K (2013) Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components. J Thromb Haemost 11:529–538. CrossRefGoogle Scholar
  150. Ruggeri ZM (2003) von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335–1342. CrossRefGoogle Scholar
  151. Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67:395–424. CrossRefGoogle Scholar
  152. Sahoo SK, Labhasetwar V (2003) Nanotech approaches to delivery and imaging drug. Drug Discov Today 8:1112–1120. CrossRefGoogle Scholar
  153. Samadi N, Golkaran D, Eslamifar A, Jamalifar H, Fazeli MR, Mohseni FA (2009) Intra/extracellular biosynthesis of silver nanoparticles by an autochtonous strain of Proteus mirabilis isolated from photographic waste. J Biomed Nanotechnol 5:247–253. CrossRefGoogle Scholar
  154. Sanhai WR, Sakamoto JH, Canady R, Ferrari M (2008) Seven challenges for nanomedicine. Nat Nanotechnol 3:242–244. CrossRefGoogle Scholar
  155. Sathyavathi R, Krishna MB, Rao SV, Saritha R, Rao DN (2010) Biosynthesis of silver nanoparticles using Coriandrum sativum leaf extract and their application in nonlinear optics. Adv Sci Lett 3:138–143. CrossRefGoogle Scholar
  156. Sato M, Webster TJ (2004) Nanobiotechnology: implication for the future of nanotechnology in orthopaedic applications. Expert Rev Med Devices 1:105–114CrossRefGoogle Scholar
  157. Sau TK, Rogach AL (2010) Nanospherical noble metal nanoparticles: colloid-chemical synthesis and morphology control. Adv Mater 22:1781–1804. CrossRefGoogle Scholar
  158. Schaller J (2008) Human blood plasma proteins: structure and function. Wiley., Ltd. X, 2008, Hoboken, p 526CrossRefGoogle Scholar
  159. Senapati S, Ahmad A, Khan MI, Sastry M, Kumar R (2005) Extracellular biosynthesis of bimetallic Au-Ag alloy nanoparticles. Small 1:517–520. CrossRefGoogle Scholar
  160. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S (2007) Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomed Nanotechnol Biol Med 3:168–171. CrossRefGoogle Scholar
  161. Shan NB, Bischof JC (2013) Blood protein and blood cell interactions with gold nanoparticles: the need for in vivo studies. BioNanoMat 14:65–79. CrossRefGoogle Scholar
  162. Sharma V, Yngard R, Lin Y (2009) Silver nanoparticles: green synthesis and their antimicrobial activities. Adv Colloid Interf Sci 145:83–96. CrossRefGoogle Scholar
  163. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D (2009) Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 3:1357–1364. CrossRefGoogle Scholar
  164. Shulman I, Smith CH (1952) Hemorrhagic disease in an infant due to deficiency of a previously undescribed clotting factor. Blood 7:794–807Google Scholar
  165. Singh N, Chaudhary A, Abraham J (2014) Susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA) and biological role of silver nanoparticles of honey against MRSA. J Biol Active Prod Nat 4:332–342. CrossRefGoogle Scholar
  166. Skocaj M, Filipic M, Petkovic J, Novak S (2011) Titanium dioxide in our everyday life; is it safe? Radiol Oncol 45:227–247. CrossRefGoogle Scholar
  167. Smith SA, Morrissey JH (2008) Polyphosphate enhances fibrin clot structure. Blood 112:2810–2816. CrossRefGoogle Scholar
  168. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH (2006) Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 103:903–908. CrossRefGoogle Scholar
  169. Sosnovik DE, Nahrendorf M, Weissleder R (2008) Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol 103:122–130. CrossRefGoogle Scholar
  170. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ (2008) Biological application of gold nanoparticles. Chem Soc Rev 37:1896–1908. CrossRefGoogle Scholar
  171. Spronk HM, Van Der Voort D, Ten Cate H (2004) Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2:12. CrossRefGoogle Scholar
  172. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51:189–197. CrossRefGoogle Scholar
  173. Sun D (2010) Nanotheranostics: integration of imaging and targeted drug delivery. Mol Pharmacol 7:1879CrossRefGoogle Scholar
  174. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, Jean-Marie U, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, Warburton EA (2009) The ATHEROMA (Atorvastatin therapy: effects on reduction of macrophage activity) study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 53:2039–2050. CrossRefGoogle Scholar
  175. Tang J, Lobatto ME, Read JC, Mieszawska AJ, Fayad ZA, Mulder WJ (2012) Nanomedical theranostics in cardiovascular disease. Curr Cardiovasc Imaging Rep 5:19–25. CrossRefGoogle Scholar
  176. Thirumalai AV, Prabhu D, Soniya M (2010) Stable silver nanoparticles synthesizing methods and its applications. J Biol Sci Res 1:259–270Google Scholar
  177. Tian Y, Zhao Y, Zheng W, Zhang W, Jiang X (2014) Antithrombotic functions of small molecule capped gold nanoparticles. Nanoscale 6:8543–8550. CrossRefGoogle Scholar
  178. Tolaymat T, ElBadawy A, Genaidy A, Scheckel K, Luxton T, Suidan M (2010) An evidence-based environmental perspective of manufactured silver nanoparticles in syntheses and applications: a systematic review and critical appraisal of peer-reviewed scientific papers. Sci Total Environ 408:999–1006. CrossRefGoogle Scholar
  179. Tong R, Cheng JJ (2007) Anticancer polymeric nanomedicines. Polym Rev 47:345–381CrossRefGoogle Scholar
  180. Tran TD, Caruthers SD, Hughes M, Marsh JN, Cyrus T, Winter PM, Neubauer AM, Wickline SA, Lanza GM (2007) Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine 2:515–526Google Scholar
  181. Triplett DA (2000) Coagulation and bleeding disorders: review and update. Clin Chem 46:1260–1269Google Scholar
  182. Uddin MJ, Emran TB, Nath AK, Jenny A, Dutta M, Morshed MM (2013) Thrombolytic activity of Spilienthes calva and Leucas zeylanica. Mol Clin Pharm 4:32–37Google Scholar
  183. Undas A, Ariëns RA (2011) Fibrin clot structure and function a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:e88–e99. CrossRefGoogle Scholar
  184. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4:1029–1036. CrossRefGoogle Scholar
  185. Undas A, Kolarz M, Kopeć G, Tracz W (2008) Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dialys Transplant 23:2010–2015. CrossRefGoogle Scholar
  186. Undas A, Nowakowski T, Cieśla-Dul M, Sadowski J (2011) Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitisobliterans. Atherosclerosis 215:481–486. CrossRefGoogle Scholar
  187. Valdyanathan R, Gopalram S, Kalishwaralal K, Deepak V, Pandian SR, Gurunathan S (2010) Enhanced silver nanoparticle synthesis by optimization of nitrate reductase activity. Colloids Surf B: Biointerf 75:335–341. CrossRefGoogle Scholar
  188. Verma VC, Kharwar RN, Gange AC (2010) Biosynthesis of antimicrobial silver nanoparticles by the endophytic fungus Aspergillus clavatus. Nanomedicine 5:33–40. CrossRefGoogle Scholar
  189. von Willebrand EA (1931) Uber hereditare pseudohamophilie (On hereditary pseudohemophilia). Acta Med Scand 76:521–549CrossRefGoogle Scholar
  190. Wang X, Gkanatsas Y, Palasubramaniam J, Hohmann JD, Chen YC, Lim B, Hagemeyer CE, Peter K (2016) Thrombus-targeted theranostic microbubbles: a new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranost 6:726–738. CrossRefGoogle Scholar
  191. Warner S (2004) Diagnostics + therapy = theranostics: strategy requires teamwork, partnering, and tricky regulatory maneuvering. Scientist 18:38–40Google Scholar
  192. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422. CrossRefGoogle Scholar
  193. Weinberg MD, Lau JF, Rosenfield K, Olin JW (2011) Peripheral artery disease. Part 2: Medical and endovascular treatment. Nat Rev Cardiol 8:429–441. CrossRefGoogle Scholar
  194. Weir A, Westerhoff P, Fabricius L, Hristovski K, von Goetz N (2012) Titanium dioxide nanoparticles in food and personal care products. Environ Sci Technol 46:2242–2250. CrossRefGoogle Scholar
  195. WHO (2011) Global status report on non-communicable diseases. Geneva. Accessed on 17 Oct 2016
  196. Wijnhoven SW, Peijnenburg WJ, Herberts CA, Hagens WI, Oomen AG, Heugens EH, Roszek B, Bisschops J, Gosens I, Van De Meent D, Dekkers S (2009) Nanosilver–a review of available data and knowledge gaps inhuman and environmental risk assessment. Nanotoxicology 3:109–138. CrossRefGoogle Scholar
  197. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H (2006) Endothelial ανβ3 integrin–targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26:2103–2109. CrossRefGoogle Scholar
  198. Wolberg AS, Campbell RA (2008) Thrombin generation, fibrin clot formation and hemostasis. Transfus Apheresis Sci 38:15–23. CrossRefGoogle Scholar
  199. Woodside DG, Liu S, Ginsberg MH (2001) Integrin activation. Thromb Haemost 86:316–323CrossRefGoogle Scholar
  200. Zhao Y, Sun X, Zhang G, Trewyn BG, Slowing II, Lin VS (2011) Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 5:1366–1375. CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Agbaje Lateef
    • 1
    • 2
    Email author
  • Sunday Ayotunde Ojo
    • 2
  • Joseph Adetunji Elegbede
    • 2
  • Paul Oluwadamilare Akinola
    • 2
  • Emmanuel Olufemi Akanni
    • 3
  1. 1.Nanotechnology Research Group (NANO+)Ladoke Akintola University of TechnologyOgbomosoNigeria
  2. 2.Laboratory of Industrial Microbiology and Nanobiotechnology, Department of Pure and Applied BiologyLadoke Akintola University of TechnologyOgbomosoNigeria
  3. 3.Division of Hematology, Department of Medical Laboratory ScienceLAUTECH College of Health SciencesOsogboNigeria

Personalised recommendations